{"created":"2023-05-15T14:38:10.327814+00:00","id":49254,"links":{},"metadata":{"_buckets":{"deposit":"50fc9bf0-f9ef-40e0-83c7-7770e4684347"},"_deposit":{"created_by":1,"id":"49254","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"49254"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00049254","sets":["1"]},"author_link":["746091","746087","746085","746090","746083","746086","746088","746089","746084"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"222","bibliographicPageStart":"216","bibliographicVolumeNumber":"506","bibliographic_titles":[{"bibliographic_title":"Biochemical and Biophysical Research Communications"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Rheumatoid arthritis (RA) is a chronic disease with systemic inflammation resulting in destruction of multiple articular cartilages and bones. Activated macrophage plays a pivotal role during the disease course and has been one of main targets to inhibit inflammatory reaction of RA by using biological disease-modifying anti-rheumatic drugs (bDMARDs). 18F-FEDAC is one of PET imaging agents targeting TSPO, which is overexpressed in activated macrophages. The aim of this study was to evaluate the roles of 18F-FEDAC PET as an in vivo imaging of activated macrophages on etanercept (ETN), a TNF-antagonist as one of bDMARDs in collagen induced arthritis mice. In RAW 264.7 cells, the expressions of TSPO as well as iNOS and infiltrated nucleus of NF-κB were induced by activation with lipopolysaccharide and interferon-gamma. TSPO expression was slightly attenuated by ETN treatment, not by methotrexate (MTX) as a cytotoxic agent. However, cell uptake of 18F-FEDAC did not show significant changes according to both of the treatments. Similarly in CIA mice, 18F-FEDAC uptake in inflamed paws on PET imaging did not show significant changes during both of the treatments, contrary to the uptake decrease of 18F-FDG, a glucose analog to reflect metabolic or active inflammatory activity. Interestingly, when we divided joints according to the degree of 18F-FEDAC uptake before ETN treatment, the joints of high 18F-FEDAC uptake showed better response to ETN than the joints with low 18F-FEDAC uptakes. In case of 18F-FDG, there was no such kinds of patterns. We can speculate that 18F-FEDAC PET imaging may identify activated macrophage-induced arthritis because that 18F-FEDAC can reflect activated macrophages, which is the therapeutic target of ETN by TNF antagonistic effect. Thus, in vivo imaging using 18F-FEDAC may be used as a predictor of therapeutic effects among those kinds of bDMARDs having anti-inflammatory actions to inhibit activated macrophage.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.bbrc.2018.10.083","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0006-29110","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Seock-Jin, Chung"}],"nameIdentifiers":[{"nameIdentifier":"746083","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Youn, Hyewon"}],"nameIdentifiers":[{"nameIdentifier":"746084","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Jin Jeong, Eun"}],"nameIdentifiers":[{"nameIdentifier":"746085","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Rong Park, Cho"}],"nameIdentifiers":[{"nameIdentifier":"746086","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Jeong Kim, Mi"}],"nameIdentifiers":[{"nameIdentifier":"746087","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Wook Kang, Keon"}],"nameIdentifiers":[{"nameIdentifier":"746088","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang"}],"nameIdentifiers":[{"nameIdentifier":"746089","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Jeong Cheon, Gi"}],"nameIdentifiers":[{"nameIdentifier":"746090","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"746091","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-11-15"},"publish_date":"2018-11-15","publish_status":"0","recid":"49254","relation_version_is_last":true,"title":["In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T01:15:08.930209+00:00"}